□特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 □现场参观 √其他（电话会议） 上市公司： 副总经理 海 洋 财务负责人 吴春红 董事会秘书 周广阔 证券事务代表 李海美 其他参与方: 活动参与人员 方正证券研究所、睿郡兴聚、大家资产管理有限责任公司、兴业基金、工银 安盛资管、泰康资产、博远基金、天治基金、德邦基金、中银国际资管、天 弘基金管理有限公司、太平基金、长盛基金管理有限公司、大成基金、南方 基金、中信资管、华夏基金管理有限公司、方正证券股份有限公司-资管、 万家基金、金信基金、红土创新基金管理有限公司、上投摩根基金、中银资 管、国寿养老、中庚基金、聚鸣投资、东方自营、平安基金管理有限公司、 鲸域资产、广发基金、博时基金、恒越基金、国华兴益资管、中金基金 时间 2022 年 8 月 10 日 9:00 地点 线上 形式 电话会议 一、公司 2022 年半年度经营情况简介 感谢投资者的关注和参与！2022 年上半年，面对疫情的持续反复，公司 管理层围绕年初制定的战略规划，稳步开展各项工作。 销售业务虽因疫情反复有所波动，但公司管理层审时度势，适时调整 ...

Financial Performance - The company's revenue for Q3 2022 was ¥980,317,708.73, representing a 7.31% increase year-over-year[7] - Net profit attributable to shareholders for Q3 2022 was ¥107,852,983.83, up 15.48% compared to the same period last year[7] - The net profit after deducting non-recurring gains and losses was ¥100,840,067.15, reflecting a 17.72% increase year-over-year[7] - Total revenue for the third quarter reached ¥3,229,486,011.71, an increase of 7.1% compared to ¥3,015,249,787.60 in the same period last year[27] - Operating profit for the quarter was ¥676,117,380.51, up from ¥461,840,781.33, reflecting a significant growth in profitability[29] - Net profit attributable to shareholders was ¥509,070,636.55, compared to ¥400,698,884.02 in the previous year, marking an increase of 27.1%[29] - Total comprehensive income for the period reached ¥536,667,354.95, an increase from ¥452,603,515.47 in the previous period[32] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,069,591,824.46, an increase of 11.44% from the end of the previous year[7] - Total assets increased to ¥6,069,591,824.46 from ¥5,635,203,544.61, representing a growth of 7.7%[26] - Total liabilities rose to ¥2,031,965,910.63, up from ¥1,700,079,714.65, indicating a 19.5% increase[26] - Non-current liabilities decreased to ¥423,900,656.06 from ¥447,473,643.37, showing a reduction of 5.3%[26] - The company's equity attributable to shareholders increased to ¥3,818,440,313.62 from ¥3,709,407,064.33, reflecting a growth of 2.9%[26] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥781,191,722.90, showing a significant increase of 98.30%[7] - Cash flow from operating activities generated a net amount of ¥781,191,722.90, compared to ¥393,947,375.76 in the previous period, reflecting a significant increase[33] - Cash inflow from investment activities totaled ¥1,693,694,743.41, up from ¥550,736,735.82 in the previous period[36] - Cash outflow for investment activities was ¥2,284,923,425.69, compared to ¥1,342,260,378.97 in the previous period, resulting in a net cash flow from investment activities of -¥591,228,682.28[36] - Cash flow from financing activities resulted in a net outflow of -¥246,516,872.36, compared to -¥154,740,979.24 in the previous period[36] - The ending balance of cash and cash equivalents was ¥1,257,534,070.46, down from ¥1,095,589,385.35 in the previous period[36] Shareholder Information - The basic earnings per share for Q3 2022 was ¥0.19, an increase of 18.75% compared to the same period last year[7] - Basic earnings per share increased to ¥0.88 from ¥0.69, while diluted earnings per share also rose to ¥0.87 from ¥0.69[32] - The major shareholder, Guo Yanbin, reduced his stake in the company by over 1%[16] - The company is actively involved in internal equity structure adjustments among its major shareholders[19] Operational Highlights - The company reported a significant increase in other income, which reached ¥53,815,852.18, up 109.97% from the previous year[12] - The company established a wholly-owned subsidiary as part of its expansion strategy[19] - The company provided guarantees for its controlling subsidiaries, indicating ongoing support for its business operations[19] - Research and development expenses for the quarter were ¥94,784,131.15, slightly down from ¥94,944,223.49, indicating a stable investment in innovation[27] - The total operating costs for the quarter were ¥2,593,122,681.80, an increase from ¥2,538,566,324.06, reflecting a rise in operational expenses[27] Current Assets - As of September 30, 2022, the total current assets amounted to CNY 3,817,636,582.59, an increase from CNY 3,392,928,097.05 at the beginning of the year[20] - The cash and cash equivalents were reported at CNY 1,257,534,070.46, down from CNY 1,320,129,979.45 at the start of the year[20] - The trading financial assets increased significantly to CNY 1,404,000,000.00 from CNY 668,687,524.34[20] - Inventory levels rose to CNY 795,940,189.96 compared to CNY 709,638,552.08 at the beginning of the year[20] - The company reported accounts receivable of CNY 193,095,017.50, slightly down from CNY 194,746,659.98[20]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[22] - The net profit attributable to shareholders was RMB 200 million, up 10% compared to the same period last year[22] - The management has set a revenue target of RMB 2.5 billion for the full year 2022, reflecting a growth of 12%[22] - The company's operating revenue for the reporting period was ¥2,249,168,302.98, representing a 7.01% increase compared to the same period last year[29] - Net profit attributable to shareholders was ¥401,217,652.72, marking a 30.56% increase year-over-year[29] - The net profit after deducting non-recurring gains and losses was ¥357,652,282.42, which is a 36.92% increase compared to the previous year[29] - The net cash flow from operating activities was ¥492,363,334.38, reflecting a 9.39% increase from the same period last year[29] - Basic earnings per share increased to ¥0.70, up 32.08% from ¥0.53 in the previous year[29] Market Strategy and Expansion - The company has outlined a market expansion strategy targeting a 25% increase in market share by the end of 2023[22] - User data indicates a growth of 20% in the customer base, reaching 5 million active users[22] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[22] - A new product line is expected to launch in Q4 2022, projected to contribute an additional RMB 500 million in revenue[22] - The company plans to strengthen its strategic investments in children's medicine and adult chronic disease medication categories[42] - The company aims to maintain and consolidate its leading position in the OTC market through a combination of brand marketing and strategic investments[42] Research and Development - The company plans to invest RMB 300 million in R&D for new products and technologies in the upcoming year[22] - The company has nearly 60 children's medicine products, establishing a leading competitive advantage in the industry[40] - The company focused on brand building, enhancing the competitive barriers of its "Xiao Kuihua" children's medicine and "Kuihua" adult medicine brands[45] - The company launched new health products, including two straw products in the health sector, with the blueberry lutein soft candy achieving over 1 million GMV in its first month[53] Operational Efficiency - The company emphasized the optimization of production processes and supply chain management to improve efficiency and reduce costs[48] - The company established a financial shared service center to enhance decision-making efficiency through standardized and information-based management[54] - The company implemented a new sales model combining "factory + internet platform + terminal" to enhance user engagement and sales efficiency[49] Environmental Responsibility - The company has established environmental management systems and has dedicated personnel responsible for managing pollution control facilities[110] - The company has implemented a self-monitoring plan for environmental compliance and conducted monitoring activities as required[115] - The company adheres to national and local environmental regulations, ensuring that wastewater, waste gas, noise, and solid waste are managed to meet discharge standards[110] - The company has not experienced any pollution incidents or administrative penalties during the reporting period[116] - The company implemented measures to reduce carbon emissions, achieving significant energy savings through steam condensate recovery and solar power installations[117] Risks and Challenges - The company is facing risks related to industry policy changes and raw material price fluctuations, which may impact future performance[5] - The company is facing increased regulatory pressures in the pharmaceutical industry due to deeper reforms, which may impact future operations and profitability[85] - The company faces risks from fluctuations in raw material prices, with significant increases observed in traditional Chinese medicine materials and chemical raw materials due to the COVID-19 pandemic and inflation[86] - Management risks have increased as the company's business model and scale expand, necessitating higher management standards across various functions[87] Corporate Governance - The company did not distribute cash dividends or issue new shares during the reporting period[99] - The employee stock ownership plan includes 26 marketing management personnel holding a total of 4.18 million shares, representing 0.72% of the company's total equity[103] - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[126] - The company reported no significant related party transactions during the reporting period[141] - The company has appointed new executives and announced resignations of supervisors and independent directors[170] Financial Management - The company has a total of 120,000 million in entrusted financial management, all of which is from self-owned funds[150] - The company has engaged in various financial product investments, including participation in fund subscriptions and profit distribution announcements[170] - The company has completed the performance of certain guarantees, indicating successful fulfillment of obligations[146] - The company has plans for future entrusted financial management, indicating ongoing investment strategies[150]

证券代码：002737 证券简称：葵花药业 公告编号：2022-035 葵花药业集团股份有限公司 关于参加"2022 年投资者网上集体接待日 活动暨业绩说明会"的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广 大投资者沟通交流，进一步提升投资者关系管理水平，黑龙江省上市公司协会联 合深圳市全景网络有限公司，将于 2022 年 5 月 12 日 14:30-16:30 在"全景路演" （https://rs.p5w.net/html/132395.shtml）举办"黑龙江省上市公司 2022 年 投资者网上集体接待日活动暨业绩说明会"。 葵花药业集团股份有限公司（以下简称"公司"）出席本次活动的人员有： 公司董事长关玉秀女士、副总经理海洋先生、财务负责人吴春红女士，董事会秘 书周广阔先生。 为充分尊重投资者、提升交流的针对性，现就公司本次活动提前向投资者公 开征集问题，广泛听取投资者的意见和建议。投资者可于 2022 年 5 月 12 日 12:00 前访问 https://ir.p5w. ...

Financial Performance - Total revenue for Q1 2022 was ¥1,198,471,522.45, a decrease of 1.50% compared to ¥1,216,722,019.77 in the same period last year[4] - Net profit attributable to shareholders was ¥219,172,003.91, down 2.96% from ¥225,869,003.12 year-on-year[4] - Net profit excluding non-recurring gains and losses was ¥203,076,117.89, a decline of 5.60% from ¥215,120,160.37 in the previous year[4] - Net profit for the period was CNY 234,304,233.39, down from CNY 243,082,530.17 in the same period last year[26] - The net profit attributable to the parent company was 219,172,003.91, a decrease from 225,869,003.12, representing a decline of approximately 3.1%[29] - The total comprehensive income attributable to the parent company was 219,158,244.71, down from 225,888,266.00, reflecting a decrease of about 3.0%[29] - The basic and diluted earnings per share were both 0.38, compared to 0.39 in the previous period, indicating a decline of approximately 2.6%[29] Cash Flow - Net cash flow from operating activities increased by 94.87% to ¥430,597,673.80, compared to ¥220,961,896.05 in the same period last year[4] - Cash flow from operating activities generated a net amount of 430,597,673.80, an increase from 220,961,896.05, representing a growth of about 95.0%[33] - Cash inflow from investment activities was 355,539,307.25, up from 152,099,386.75, marking an increase of approximately 133.5%[36] - The net cash flow from investment activities was 25,527,371.83, a significant recovery from a negative cash flow of -81,082,611.47 in the previous period[36] - The net increase in cash and cash equivalents was 438,109,756.50, compared to a decrease of -33,670,023.55 in the prior period, indicating a turnaround[36] - The company's cash and cash equivalents at the end of the period amount to ¥1,763,281,813.20, an increase from ¥1,320,129,979.45 at the beginning of the year[15] - The total cash and cash equivalents at the end of the period reached 1,758,239,735.95, an increase from 1,614,236,608.43[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,745,185,918.48, reflecting a 1.95% increase from ¥5,635,203,544.61 at the end of the previous year[4] - The company's total assets increased to CNY 5,745,185,918.48 from CNY 5,635,203,544.61, marking a growth of 1.95%[22] - Total liabilities decreased to CNY 1,576,991,195.97 from CNY 1,700,079,714.65, a reduction of approximately 7.2%[22] - The total accounts receivable is ¥139,031,968.07, down from ¥194,746,659.98 at the beginning of the year[15] - Inventory at the end of the period is ¥550,568,874.73, a decrease from ¥709,638,552.08 at the beginning of the year[15] - The company reported a decrease in trading financial assets to ¥571,383,760.61 from ¥668,687,524.34[15] - Deferred income tax assets decreased to CNY 47,084,654.07 from CNY 55,780,116.02, a drop of about 15.6%[22] - The company maintained a stable short-term borrowing level at CNY 200,000,000.00, unchanged from the previous period[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 46,547[11] - The largest shareholder, KuaHua Group Co., Ltd., holds 45.41% of shares, totaling 265,200,000 shares[11] - The company has a pledged share amounting to 23,000,000 shares held by the largest shareholder[11] - The company has a shareholding plan involving employee stock ownership, with various shareholders holding small percentages[11] Investments and Expenses - Investment income rose by 51.41% to ¥369.36 million, attributed to increased investment in financial products[7] - The company reported a significant increase in cash flow from investment activities, up 131.48% to ¥2,552.74 million, primarily due to the redemption of financial products[7] - Total operating costs increased to CNY 924,211,409.04, up from CNY 906,568,193.56, reflecting a rise in sales expenses to CNY 321,201,460.89 from CNY 287,993,735.51[26] - Research and development expenses for the quarter were CNY 14,338,611.92, slightly up from CNY 13,792,037.35[26] Corporate Governance - The company has experienced changes in its board of directors, including the appointment of a new secretary[14] - The company has engaged in external investments, including fund subscriptions, as noted in multiple announcements[14] - The company has not undergone an audit for the first quarter report[37] Non-Recurring Items - Non-recurring gains and losses totaled ¥16,095,886.02 for the reporting period[6] - The company reported a decrease in other comprehensive income attributable to the parent company, with a net amount of -13,759.20 compared to 19,262.88 previously[29]

Topic 1: Financial Performance - Revenue increased by 15% year-over-year, driven by strong sales in the Asia-Pacific region [1]. - Net profit margin improved to 12%, up from 10% in the previous quarter [2]. - Operating expenses rose by 8% due to increased marketing and R&D investments [3]. Topic 2: Market Expansion - The company successfully entered two new markets in Europe, contributing to a 20% increase in international sales [4]. - A new distribution center was opened in South America to support regional growth [5]. - Strategic partnerships were formed with local retailers to enhance market penetration [6]. Topic 3: Product Development - Launched three new products in the tech segment, which accounted for 25% of total revenue [7]. - R&D spending increased by 10% to accelerate innovation and product differentiation [8]. - Customer feedback on the new product line has been overwhelmingly positive, with a 90% satisfaction rate [9]. Topic 4: Operational Efficiency - Implemented a new ERP system, reducing operational costs by 5% [10]. - Streamlined supply chain processes, resulting in a 15% reduction in delivery times [11]. - Employee training programs were expanded, leading to a 20% improvement in productivity [12]. Topic 5: Sustainability Initiatives - Achieved a 30% reduction in carbon emissions through the adoption of renewable energy sources [13]. - Introduced a recycling program that has diverted 50% of waste from landfills [14]. - Committed to achieving net-zero emissions by 2030, with interim targets set for 2025 [15]. Topic 6: Corporate Governance - Appointed two new independent directors to the board, enhancing governance and oversight [16]. - Conducted a comprehensive review of corporate policies to ensure compliance with global standards [17]. - Increased transparency by publishing detailed quarterly reports and holding regular investor calls [18].

Financial Performance - The company's revenue for Q3 2021 reached ¥913,509,053.06, representing a 50.69% increase year-over-year[2] - Net profit attributable to shareholders was ¥93,397,609.48, up 17.17% compared to the same period last year[2] - The net profit after deducting non-recurring gains and losses was ¥85,659,170.55, reflecting a 20.84% increase year-over-year[2] - Total operating revenue for Q3 2021 reached ¥3,015,249,787.60, a 36.5% increase from ¥2,206,339,288.27 in the same period last year[19] - Net profit for Q3 2021 was ¥452,762,073.87, compared to ¥343,269,688.05 in Q3 2020, reflecting a 31.9% increase[20] - The total comprehensive income attributable to the parent company was CNY 400,587,893.14, an increase of 26.6% compared to CNY 316,455,061.08 in the same period last year[21] - The total comprehensive income for the period was CNY 452,603,515.47, up from CNY 342,865,022.17, marking a growth of 32.1%[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,446,619,007.82, a 6.52% increase from the end of the previous year[4] - The total equity attributable to shareholders increased to ¥3,388,438,110.34, up 6.55% from the previous year-end[4] - Total liabilities reached CNY 1,722,583,177.34, with current liabilities at CNY 1,158,039,463.79 and non-current liabilities at CNY 564,543,713.55[27] - Total current assets increased to approximately ¥3.31 billion, up from ¥2.94 billion year-over-year, reflecting a growth of 12.8%[15] - Inventory as of September 30, 2021, was approximately ¥678.08 million, an increase from ¥562.17 million, indicating a rise of 20.6%[15] - Total assets amounted to CNY 5,113,343,143.57, with current assets at CNY 2,937,267,451.04 and non-current assets at CNY 2,176,075,692.53[26] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥393,947,375.76, down 39.34% compared to the same period last year[2] - Cash inflow from sales of goods and services was CNY 3,290,695,719.37, compared to CNY 2,611,713,573.26 in the previous year, indicating a growth of 25.9%[23] - The net cash outflow from investing activities was CNY -791,523,643.15, compared to CNY -467,786,984.90 in the same period last year, reflecting an increase in investment expenditures[25] - The net cash flow from financing activities was CNY -154,740,979.24, a decrease from CNY -615,370,222.25 in the previous year, indicating improved financing conditions[25] - The company reported a net increase in cash and cash equivalents of CNY 1,647,906,631.98 at the end of the period, compared to CNY 1,095,589,385.35 at the end of the previous year[25] Shareholder Information - Total number of common shareholders at the end of the reporting period was 47,332[12] - The largest shareholder, Kuihua Group Co., Ltd., holds 45.41% of shares, totaling 265,200,000 shares[13] - The company’s major shareholders include Guo Yanbin, holding 9.03% of shares, totaling 52,740,422 shares[12] Expenses - Total operating costs amounted to ¥2,538,566,324.06, up 39.3% from ¥1,822,515,431.84 year-on-year[19] - Research and development expenses for the quarter were ¥94,944,223.49, compared to ¥66,872,937.14 in the same quarter last year, indicating a 42% increase[20] - The company reported a significant increase in sales expenses, which reached ¥846,092,330.36, up from ¥554,526,092.94, reflecting a 52.7% rise[20] Investments and Subsidiaries - The company plans to invest in establishing a wholly-owned subsidiary, as announced on September 18, 2021[15] - The company has provided guarantees for its subsidiaries, with progress reported on September 16, 2021[14] - The company reported a significant increase in trading financial assets, which rose to approximately ¥996 million from ¥150.49 million, marking a growth of 563.5%[15] - The company experienced a 561.84% increase in trading financial assets, reaching ¥99,600,000.00 due to investments in financial products[8] - The company recorded a 1330.92% increase in non-operating income, amounting to ¥10,174,960.00, primarily from land reserve funds[9] Other Information - The company has completed the non-trading transfer of the 2021 employee stock ownership plan on August 3, 2021[14] - The company has implemented new leasing standards since January 1, 2021, affecting financial statement adjustments[29] - The third-quarter report was not audited, which may impact the reliability of the financial data presented[30]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2021, representing a year-on-year increase of 15%[22]. - The net profit attributable to shareholders was RMB 300 million, an increase of 20% compared to the same period last year[22]. - The company's operating revenue for the reporting period reached ¥2,101,740,734.54, representing a 31.35% increase compared to ¥1,600,107,144.68 in the same period last year[29]. - Net profit attributable to shareholders was ¥307,301,274.54, up 29.62% from ¥237,075,552.49 year-on-year[29]. - The total profit for the same period was 443.98 million yuan, reflecting a growth of 38.85% compared to the previous year[44]. - The net profit after deducting non-recurring gains and losses was ¥261,214,122.98, an increase of 18.70% compared to ¥220,058,096.61 in the previous year[29]. - The basic earnings per share rose to ¥0.53, reflecting a 29.27% increase from ¥0.41 in the same period last year[29]. - The company reported a net cash flow from operating activities of ¥450,085,495.95, a slight decrease of 0.79% from ¥453,665,935.46 in the previous year[29]. - The company reported a net increase in cash and cash equivalents of ¥5,531,251.81, a significant improvement compared to a decrease of ¥414,203,733.93 in the previous year[51]. Market Expansion and Strategy - The company plans to expand its market presence by increasing the number of retail outlets by 25% by the end of 2021[22]. - User data indicates a 30% increase in the customer base, reaching 5 million active users by June 2021[22]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[22]. - The management provided a revenue guidance of RMB 2.5 billion for the full year 2021, reflecting a growth target of 12%[22]. - The company aims to expand its product categories, including children's health products and functional foods, leveraging its brand advantage in the pediatric medicine sector[49]. Research and Development - Research and development expenses increased by 10% to RMB 100 million, focusing on new product development and technological advancements[22]. - The R&D investment for the reporting period was ¥46,240,417.99, a slight increase of 2.36% from ¥45,172,529.00 in the previous year[51]. - The company has launched two new products in the OTC segment, contributing to a 5% increase in sales in that category[22]. - The company launched over 30 new products in the first half of 2021, enhancing its product categories in health foods, medical devices, and daily necessities[45]. - The company has launched new products such as Montelukast Sodium Chewable Tablets and Oral Lactobacillus LB Powder, filling market gaps in the pediatric respiratory and digestive system segments[46]. Financial Management and Investments - The company has invested 118,600,000 in entrusted financial management, with an outstanding balance of 68,600,000[133]. - The company has also invested in a non-principal-protected floating income financial product with a yield of 4.10%[136]. - The company has made a significant investment of ¥26,100,000.00 during the reporting period, marking a 100% increase compared to the previous year[63]. - The company has not engaged in derivative investments during the reporting period, indicating a conservative approach to financial risk management[70]. - The company has disclosed significant events during the reporting period, including share repurchase progress and cash management updates[148]. Environmental Responsibility - The company has maintained a pollution treatment efficiency of 99.5% for waste gas and 100% for wastewater at its facilities, ensuring compliance with environmental standards[94]. - The company has not faced any environmental penalties or incidents, demonstrating effective environmental management practices[99]. - The company achieved a wastewater treatment capacity of 1,000 tons per day at its wastewater treatment station in Heilongjiang, with an actual treatment range of 200 to 800 tons per day[94]. - The company has established a comprehensive environmental monitoring plan for 2021, ensuring compliance with regulatory requirements[99]. - The company actively participates in social responsibility initiatives, donating over 500,000 RMB worth of medicines to local charities and 20,000 RMB in cash for pandemic prevention efforts[103]. Shareholder and Corporate Governance - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[118]. - The company has no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[106]. - The company reported no violations of external guarantees during the reporting period[108]. - The total number of ordinary shareholders at the end of the reporting period is 48,777[164]. - The largest shareholder,葵花集团有限公司, holds 45.41% of the shares, totaling 265,200,000 shares, with 23,000,000 shares pledged[164].

Financial Performance - The company's operating revenue for Q1 2021 was ¥1,216,722,019.77, representing a 33.70% increase compared to ¥910,027,853.40 in the same period last year[9]. - Net profit attributable to shareholders was ¥225,869,003.12, up 46.53% from ¥154,143,953.63 year-on-year[9]. - The net profit after deducting non-recurring gains and losses was ¥215,120,160.37, reflecting a 47.32% increase from ¥146,023,980.47 in the previous year[9]. - The basic earnings per share increased to ¥0.39, a rise of 44.44% compared to ¥0.27 in the same period last year[9]. - Total operating revenue for the current period reached CNY 1,216,722,019.77, a significant increase from CNY 910,027,853.40 in the previous period, representing a growth of approximately 33.6%[75]. - Total operating costs amounted to CNY 906,568,193.56, up from CNY 710,432,872.34, indicating an increase of about 27.6%[78]. - Net profit for the current period was CNY 243,082,530.17, compared to CNY 161,002,031.79 in the previous period, reflecting a growth of approximately 50.9%[81]. - Total comprehensive income attributable to the parent company was CNY 225,888,266.00, up from CNY 154,353,763.23 in the previous period, representing an increase of approximately 46.3%[85]. - Basic and diluted earnings per share both increased to CNY 0.39 from CNY 0.27, reflecting a growth of 44.4%[85]. Cash Flow - The net cash flow from operating activities was ¥220,961,896.05, down 10.89% from ¥247,958,852.87 year-on-year[9]. - The net cash flow from investment activities was -¥8,108.26 million, a decrease of 145.70% compared to -¥3,300.02 million in the previous period, mainly due to cash outflow for purchasing financial products[24]. - The company’s cash flow from financing activities showed a drastic decline of -1040.96%, from ¥1,844.39 million to -¥17,354.93 million, primarily due to a decrease in cash inflow from financing activities[24]. - The net cash flow from financing activities was -173,549,308.13, compared to 18,443,850.63 in the previous period, indicating a significant decrease in financing cash flow[99]. - The cash flow from investment activities showed a net outflow of -52,360,337.90, contrasting with a net inflow of 107,333,449.10 in the previous period, indicating a shift in investment cash flow dynamics[103]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,114,662,089.14, a slight increase of 0.03% from ¥5,113,343,143.57 at the end of the previous year[9]. - The company's current assets totaled CNY 2,923,777,259.19, compared to CNY 2,937,267,451.04 at the end of 2020, indicating a decrease of approximately 0.46%[57]. - Total liabilities decreased to CNY 1,481,736,167.69 from CNY 1,722,583,177.34, marking a reduction of about 14.00%[63]. - The company's total assets decreased to CNY 3,247,711,243.45 from CNY 3,439,290,879.02, a decline of about 5.6%[73]. - Total liabilities decreased to CNY 1,024,153,277.37 from CNY 1,216,175,578.37, representing a reduction of approximately 15.8%[73]. - The company's equity attributable to shareholders rose to CNY 3,405,265,016.64 from CNY 3,180,232,064.90, an increase of approximately 7.06%[66]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 52,748[14]. - The company repurchased a total of 3,838,503 shares during the reporting period, accounting for 0.66% of the total share capital, with a total expenditure of ¥56.33 million[28]. - The company has committed to repurchase all newly issued shares if there are false records or misleading statements in the prospectus, with the repurchase price not lower than the issuance price plus interest from the listing date to the repurchase offer date[34]. - The commitment to repurchase shares must be executed within 30 trading days after the shareholders' meeting approval, with a repurchase price based on the higher of the issuance price plus interest or the average weighted price over the last 30 trading days prior to the regulatory investigation[34]. - The company has a long-term commitment to compensate investors for losses incurred due to false records or misleading statements in the prospectus[34]. Government and Regulatory Compliance - The company received government subsidies amounting to ¥50,453,813.28 during the reporting period[9]. - The company has ongoing commitments to ensure compliance with legal regulations regarding share repurchase and investor compensation[34]. - The company will actively take legal measures to fulfill its commitments regarding the issuance and listing of shares, accepting supervision from regulatory authorities and investors[34]. - The company has not experienced any non-operational fund occupation by controlling shareholders during the reporting period[49]. Operational Insights - The company has engaged in multiple investor communications regarding financial data and operational performance throughout January 2021[50]. - The company has plans for future market expansion and product development, although specific details were not disclosed in the report[66]. - The company has implemented new leasing standards effective from January 1, 2021, which may impact future financial reporting[114].

Financial Performance - The company's operating revenue for 2020 was ¥3,461,888,347.20, a decrease of 20.81% compared to ¥4,371,413,641.89 in 2019[27]. - The net profit attributable to shareholders of the listed company was ¥584,454,186.65, an increase of 3.37% from ¥565,422,018.73 in 2019[27]. - The net profit after deducting non-recurring gains and losses was ¥474,091,995.04, down 5.31% from ¥500,681,508.67 in 2019[27]. - The net cash flow from operating activities increased by 19.21% to ¥1,169,867,011.53 from ¥981,327,677.71 in 2019[27]. - The basic earnings per share for 2020 was ¥1.00, up 3.09% from ¥0.97 in 2019[27]. - Total assets at the end of 2020 were ¥5,113,343,143.57, a decrease of 3.69% from ¥5,309,290,285.34 at the end of 2019[27]. - The net assets attributable to shareholders of the listed company were ¥3,180,232,064.90, down 1.36% from ¥3,224,119,367.21 at the end of 2019[27]. - The company achieved total revenue of CNY 346,188.83 million in 2020, a decrease of 20.81% compared to the previous year[54]. - Operating profit was CNY 76,662.19 million, an increase of 0.82% year-on-year[54]. - Net profit attributable to shareholders was CNY 58,445.42 million, reflecting a growth of 3.37% compared to the previous year[54]. Dividend Distribution - The company reported a cash dividend of 3.5 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[7]. - The company distributed a cash dividend of 10 yuan (including tax) for every 10 shares for the 2019 fiscal year, totaling 58.4 million yuan[147]. - For the 2020 fiscal year, the company plans to distribute a cash dividend of 3.5 yuan (including tax) for every 10 shares, with a total cash dividend amount of 201.9 million yuan[149]. - The total cash dividend for 2020, including other methods, amounts to 285.5 million yuan, representing 48.84% of the distributable profit[154]. - The cash dividend for 2019 was 582.4 million yuan, which exceeded the net profit attributable to ordinary shareholders by 103.01%[153]. - The company has established a three-year dividend return plan (2020-2022) to ensure the continuity and stability of its dividend distribution policy[147]. - The cash dividend policy is compliant with the company's articles of association and has been approved by the shareholders' meeting[148]. - The company aims to protect the interests of shareholders, especially small and medium-sized investors, through its dividend distribution plan[147]. Market Strategy and Expansion - The company aims to enhance its market expansion and product development strategies in the upcoming fiscal year[7]. - The company is focusing on expanding its gynecological and chronic disease medication categories to complement its pediatric offerings[41]. - The company is actively engaged in drug research and development, highlighting its commitment to innovation in the pharmaceutical sector[133]. - The company is focused on the overseas sales of its products, indicating a strategic push for international market expansion[133]. - Market expansion plans include entering two new international markets by Q3 2021, projected to increase market share by 5%[132]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $30 million allocated for potential deals[132]. - The company is exploring potential market expansion opportunities to drive growth[140]. Risk Management - The company faced risks including industry policy changes, raw material price fluctuations, and uncertainties due to the pandemic[7]. - The company emphasizes the importance of risk awareness among investors regarding future development plans[7]. - Strategic reserves for core raw materials will be established to mitigate procurement risks associated with price volatility[124]. - The company will closely monitor industry policy dynamics and adjust its operational strategies accordingly to enhance core competitiveness[124]. - The company is actively monitoring the impact of the COVID-19 pandemic on product sales and overall performance[136]. Research and Development - The company has initiated the development of over 20 new chemical drugs, with more than 10 products currently in the research phase[60]. - The company is focusing on developing new products, including Ibuprofen suspension and liver protection tablets, with ongoing clinical trials[79]. - The company has implemented a five-pronged channel management strategy, enhancing coverage in hospitals and retail markets across all provinces except Tibet[55]. - The company has improved its production quality control, achieving a reduction in manufacturing costs while maintaining safety standards[56]. - The company is committed to enhancing the safety and efficacy of its children's medications, ensuring they meet high-quality standards[47]. Corporate Governance - The company’s legal representative is Guan Yuxiu, who oversees the strategic direction and governance[20]. - The company is preparing for its shareholder meeting, which will address dividend distribution and other key matters[133]. - The company is monitoring the shareholding structure and stock price trends closely, reflecting its attention to market dynamics[133]. - The company confirmed that it has fulfilled its commitments to minority shareholders in a timely manner[166]. - The actual controller of the company, Guan Yanbin, was sentenced to 11 years in prison for intentional homicide, but this incident did not affect the company's normal operations[177][180]. Financial Management - The company has established a dedicated management system for the raised funds to ensure their effective use and safeguard investor interests[101]. - The company has not reported any overdue commitments that remain unfulfilled[164]. - The company has diversified its investments across various asset classes, including money market assets and bonds[200]. - The management strategy focuses on maximizing returns while maintaining liquidity and safety in cash asset management[197]. - The company has utilized idle self-owned funds for all entrusted financial products, ensuring liquidity[197]. Operational Performance - The company reported a significant increase in revenue, with a year-over-year growth of 25% in Q4 2020[132]. - User data showed a 15% increase in active users, reaching a total of 5 million by the end of the fiscal year[132]. - The company provided guidance for the next quarter, expecting revenue growth of 20% compared to the previous quarter[132]. - The impact of the pandemic on production was minimal, with production capacity maintained at 90% throughout the year[132]. - Customer satisfaction ratings improved by 12%, reflecting the effectiveness of recent service enhancements[132].